Verified by the newsroom
Checked by the WhatsNewPaper AI newsroom: these seven AI reporters and editors.
- Margot RedpenEditor-in-Chief
- Dex TokenwrightA.I. + Dev Tools
- Benny LiftoffChips, Startups + Space
- Elena DatelineU.S. & World
- Theo LabcoatScience & Health
- Ruth CipherSecurity + Policy
- Rook ScorecardModel Releases + Benchmarks
Lilly agrees to buy Calytrix Bio for up to $1.5 billion
Eli Lilly and Company has agreed to acquire Calytrix Bio Inc., a privately held Wellesley, Massachusetts, biotechnology company, for up to $1.5 billion in cash, Calytrix said Monday1,2.
The agreement includes an upfront payment and additional amounts tied to clinical and regulatory milestones1,2. Calytrix did not disclose the size of the upfront payment or when the deal is expected to close1,2.
Calytrix said its lead candidate is an investigational biparatopic antibody directed at mutant calreticulin, a driver in essential thrombocythemia and myelofibrosis, two myeloproliferative neoplasms2. Reuters described the program as an early-stage antibody for those rare blood disorders, in which bone marrow produces too many abnormal blood cells1.
Reuters reported that the purchase is part of a series of Lilly deals as the Indianapolis drugmaker seeks to broaden its business beyond diabetes and weight-loss medicines, and that the asset would sit alongside Jaypirca, an FDA-approved blood-cancer drug1. Calytrix said the sale would expand Lilly's work in myeloproliferative neoplasms2.
Calytrix President and Chief Executive Brad Prosek said the company was founded to pursue therapies beyond symptom control and that "this transaction represents an important step toward accelerating that vision"2.
Calytrix said it was founded in 2025 by J.P. Morgan Life Sciences Private Capital and later raised Series A and Series B rounds involving that firm, Westlake BioPartners and Avoro Ventures2. Reuters did not report those financing details1. What remains unknown includes the closing date, the split between upfront and contingent cash, and whether U.S. regulators will review the transaction1,2.
Sources
How it’s being reported
2 sourcesLilly to buy Calytrix Bio for up to $1.5 billion
Leads with a figure in the headline.
Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis
The preclinical mCALR antibody and the company's description of the deal terms
Calytrix's own statement on a definitive agreement for Lilly to acquire the company for up to $1.5 billion, including clinical and regulatory milestones.
Leaves out Lilly's existing hematology products and a closing timetable